Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

<p>Table S2: Sequence information for probes and primers used in this article.</p>

Guardado en:

Detalles Bibliográficos
Autor principal:	Nan Ding (15321526) (author)
Otros Autores:	A-Bin You (15321529) (author), Hu Yang (15321532) (author), Guo-Sheng Hu (15321535) (author), Chun-Ping Lai (15321538) (author), Wen Liu (12209560) (author), Feng Ye (15321541) (author)
Publicado:	2025
Materias:	Cancer Cancer Risk Factors Cancer Biology Molecular and Cellular Biology Immuno-oncology Epigenetics Gastrointestinal Cancers Colorectal cancer Immunology Immunomodulation Oncogenes & Tumor Suppressors Tumor suppressor genes
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
por: Nan Ding (15321526)
Publicado: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
por: Cheng-Kai Wang (14963880)
Publicado: (2025)

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
por: Christopher T. Letson (16424095)
Publicado: (2025)

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
por: Christopher T. Letson (16424095)
Publicado: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
por: Christopher T. Letson (16424095)
Publicado: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
por: Christopher T. Letson (16424095)
Publicado: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
por: Christopher T. Letson (16424095)
Publicado: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
por: Xufeng Lu (14960724)
Publicado: (2025)

Supplementary table S5 from HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer
por: Penglin Pan (14959703)
Publicado: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
por: Yun-Guang Hong (14960966)
Publicado: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
por: Yun-Guang Hong (14960966)
Publicado: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
por: Yun-Guang Hong (14960966)
Publicado: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
por: Yun-Guang Hong (14960966)
Publicado: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
por: Yun-Guang Hong (14960966)
Publicado: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
por: Yun-Guang Hong (14960966)
Publicado: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Long Jiang (14956159)
Publicado: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Long Jiang (14956159)
Publicado: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Long Jiang (14956159)
Publicado: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
por: Smruthy Sivakumar (15053536)
Publicado: (2025)

Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
por: Namhee Kim (14963603)
Publicado: (2025)

Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
por: Namhee Kim (14963603)
Publicado: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Lenka Stolarova (16547259)
Publicado: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Lenka Stolarova (16547259)
Publicado: (2025)

Table S3 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Lenka Stolarova (16547259)
Publicado: (2025)

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
por: Junfeng Xu (16437141)
Publicado: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jpuep8vlsq42a8pq6em5rf9gp8